Samhi Hotels IPO Sees Muted Response on Day 1
The initial public offering (IPO) of Samhi Hotels received a tepid response from investors on the first day of bidding, September 14. The offer has received bids for 26.73 lakh shares against the issue size of 6.25 crore shares, resulting in a subscription of 4%.
Retail investors have provided the most support to the issue, bidding for 21% of the reserved portion, which is 10% of the total offer size. High net-worth individuals (HNIs) have subscribed for 1% of their portion, which is 15% of the offer. The portion set aside for qualified institutional buyers (QIBs), which is 75%, was subscribed 0.005%.
The tepid response to the IPO is likely due to a number of factors, including the high debt levels of the company and its losses in the past few years. Samhi Hotels has not turned into profit yet, as per the financials reported in the prospectus, though managed to narrow losses year after year.
The company is planning to raise Rs 1,370.1 crore via the public issue at the upper price band. The price band for the offer, which closes on September 18, has been set at Rs 119-126 per share.
The public issue comprises a fresh issuance of shares worth Rs 1,200 crore, and an offer-for-sale of 1.35 crore shares worth Rs 170.1 crore by three investors.
Privately-held Samhi Hotels will make use of the fresh issue proceeds for repaying debts amounting to Rs 900 crore. It reported outstanding debts of Rs 2,812.5 crore on a consolidated basis including Rs 142.9 crore of FCCDs as of June 2023.
The company has raised Rs 616.54 crore via several anchor investors on September 13, including the Government of Singapore, Monetary Authority of Singapore, CLSA Global Markets, HSBC Global, Citigroup, Societe Generale, SBI Mutual Fund, ICICI Prudential, and Elara India Opportunities Fund.
The success of the IPO will depend on a number of factors, including the overall market sentiment and the appetite for hotel stocks. However, the company’s strong operating numbers and topline performance may be able to attract investors, despite the high debt levels and losses in the past few years.
Related News
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.
Leave a Reply